Alison M. Taylor
@alisontaylorlab
Followers
444
Following
166
Media
3
Statuses
88
Scientist, assistant professor at Columbia University Medical Center studying aneuploidy in cancer, posts are my own and do not represent views of CUIMC
Joined April 2018
Excited for the pub on our translational analyses suggesting different types of genomic alterations associated with response in NSCLC #jitc @BHenickMD @CatherineShuMD
New #JITC article: Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings https://t.co/0QtHDJhhzW
@BHenickMD @DrMarkAwad @BizarMd @JustinGainor @CatherineShuMD
1
0
10
Excited about our new paper out in JCO Precision Oncology! Chr8q gain and MYC enhancer amplification correlates with African ancestry in lung SCC #jcopo
https://t.co/i1WkcTYAJi
ascopubs.org
PURPOSEIn lung squamous cell carcinoma (LUSC), Black patients show significantly higher incidence and lower overall survival than White patients. Although socioeconomic factors likely contribute to...
3
1
21
Yes! We are very excited to be recruiting a shared computational biologist.
This is a fantastic opportunity to be involved in multiple projects and gain significant experience in diverse areas of cancer research within a supportive environment @Columbia. Formal job posting to come soon; DM for next steps. Re-tweets appreciated! ๐๐ผ 2/2
0
1
5
This is a fantastic opportunity to be involved in multiple projects and gain significant experience in diverse areas of cancer research within a supportive environment @Columbia. Formal job posting to come soon; DM for next steps. Re-tweets appreciated! ๐๐ผ 2/2
0
2
1
What a wonderful conference! And great talk today by lab graduate student Nadja Zhakula-Kostadinova! #AACRsynth24
Jolanta E. Grembecka, Serena J. Silver, Karen M. Cichowski, Janice Y. Lee, and Nadja Zhakula discussed "Translating the Next Synthetic Lethalities" in a plenary session at the AACR Conference on Cancer Synthetic Vulnerabilities. #AACRsynth24
0
0
9
Jolanta E. Grembecka, Serena J. Silver, Karen M. Cichowski, Janice Y. Lee, and Nadja Zhakula discussed "Translating the Next Synthetic Lethalities" in a plenary session at the AACR Conference on Cancer Synthetic Vulnerabilities. #AACRsynth24
0
1
5
Great presentation Siobhan!
Congratulations to Berger lab post-doc Dr. Siobhan OโBrien for her exciting talk on paralog dependencies!
0
0
1
I support the message my colleagues are sharing in today's @AACR Early-career Hill Day. I urge Congress to continue prioritizing medical research and support the highest possible funding increase for @NIH. #AACRontheHill @SenSchumer @SenGillibrand @RepJerryNadler
Today is the AACR Early-Career National Day of Action, and we're calling on early-career scientists, trainees, students, and all who support them to contact members of Congress and ask them to prioritize @NIH funding. Take action: https://t.co/Lo1wR2a4fu
#AACRontheHill #FundNIH
1
1
15
What a great meeting!
Great to see Dr. Alison Taylor (@alisontaylorlab) and many more researchers representing @ColumbiaMed at this week's AI Meets Cancer Research Symposium in Barcelona! Learn more about the work being presented by HICCC researchers: https://t.co/8T8sEfnzWm
0
0
14
Out @Nature today! Excited to finally share our work led by Juliann Shih in collab w/ @RameenBeroukhim. Our algorithm โBISCUTโ looks at large chromosomal changes and aneuploidy in cancer to detect genes that can account for effects on cellular fitness. https://t.co/6Z33wBX379
22
71
283
My first time attending BAMM, what a great meeting! Thanks for organizing and inviting us! @KabecheLab
Itโs a wrap! Wonderful day of cell division biology at BAMM 2023 โฆ. Thank you to all participants for making it such a fun and successful meeting, as well as fantastic co-organizers Lily Kabeche โฆ@KabecheLabโฉ and Dan Needleman, and our lab members. #BAMM #Meiosis #Mitosis
0
0
3
We are hiring a postdoctoral fellow for a fully funded position on how signaling enzymes regulate breast cancer growth! We welcome those interested in pivoting from basic biology into cancer biology.
nature.com
The Vasan Lab at the Herbert Irving Comprehensive Cancer Center seeks a postdoctoral candidate. Our laboratory specializes in breast cancer, with a...
1
17
29
Wholeheartedly agree!!
๐ข๐ขNew PIs: Apply for the NIH Early Career Reviewer (ECR) program. I recently served on a study section and learned so much about grant writing and the review process. Eligibility: 1 year in a faculty position; no R01/R01-equivalent grant https://t.co/vjDdNKqZ8E
0
0
1
Our first (of many to come๐) exciting collaborative effort(s) with the @BizarMd Lab, led by superstars Yiping Wang @joy_lfan @JCA_Melms bringing multimodal single-nucleus RNA/TCR, spatial and whole-genome seq to the #clinical arena! #cancergenomics #computationalbiology
โผ๏ธ JUST PUBLISHED @NatureGenet ๐ฐ Multimodal single-cell and whole-genome sequencing of small, frozen clinical specimens ๐ง๐ฟโ๐คโ๐ง๐ฟ @elhamazizi Ben Izar and team ๐๐ผ https://t.co/LRhcW5EnfC
9
22
104
Shoutout to this @CD_AACR paper by @CarrotJian and colleagues during the #AACRProjectGENIE session at #AACRdisp22
ICYMI in @CD_AACR: Genetic Ancestry Contributes to Somatic Mutations in #LungCancer from Admixed Latin American Populations by @CarrotJian @ogarrieta @AndresFCardonaZ Alexander Gusev, Matthew Meyerson, and colleagues #AACRdisp22
https://t.co/aWGqBowPu4
1
2
7
#Aneuploidy22 was a fabulous meeting, thanks to the organizers for putting it together!
#Aneuploidy22 was a great scientific meeting and a fantastic opportunity to honour Angelika. Thanks to all the speakers, poster presenters and attendees for sharing their science and making it a successful and vibrant conference.
0
0
6
To all the Social DNAing fans, new registration is needed due to zoom license updates. https://t.co/J3oOjMaI0d
0
6
13
Structure-Based Classification System for EGFR Mutations May Help Clinicians Personalize Treatments for More Patients
ilcn.org
Grouping mutations based on their likelihood of response to specific drug types in future EGFR TKI trials may eventually help physicians tailor treatments for patients with atypical mutations.
0
7
22